The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

You are here: Home / Society Publications

Society Publications


The Antibody Society has participated in research included in numerous publications about antibody therapeutics:

  1. Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024 Mar 6. doi: 10.1038/s41573-024-00896-6.
  2. Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. Antibodies to watch in 2024. MAbs. 2024;16(1):2297450. doi: 10.1080/19420862.2023.2297450.
  3. Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023 Jun 12.  This review provides a broad overview of the recent advances and challenges in ADC development for cancer treatment. Supplemental Tables 1 (ADC pipeline) and 2 (Terminated ADCs) are found here; Supplemental Table 3 (Alt. drug conjugates) is found here.
  4. Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs 2023; 15(1). doi.org/10.1080/19420862.2022.2153410.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2022, as of November 2022.
  5. Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs 2022; 14(1). doi.org/10.1080/19420862.2021.2014296
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2021, as of November 2021.
  6. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs 2021; 13(1). doi.org/10.1080/19420862.2020.1860476
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2020, as of November 2020.
  7. Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19. Antibody Therapeutics. 2020.
    In March 2020, the Chinese Antibody Society, in collaboration with The Antibody Society, initiated the “COVID-19 Antibody Therapeutics Tracker” program to track the antibody-based COVID-19 interventions in preclinical and clinical development globally. This paper presents exploratory data analyses and visualization to demonstrate the latest trends of COVID-19 antibody development, based on data for over 150 research and development programs and molecules included in the Tracker as of August 8th, 2020.
  8. Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020; 12(1). 
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2019, as of November 2019.
  9. Reichert JM. Anticorps médicaments  – un regard américain sur un présent et un futur fascinants [Antibody therapeutics: an American view of an amazing present and future]. Med Sci (Paris). 2019;35(12):924–925.
    This paper provides an overview of the antibody therapeutics landscape as of 2019 and offers an outlook on the future.
  10. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery 2019; 18(8):585-608.
    This paper reviews the current bispecific antibody landscape from a mechanistic perspective, and includes a comprehensive overview of the clinical pipeline.
  11. Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs 2019; 11(2):219-238.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2018, as of November 2018.
  12. Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs 2018; 10(2):183-203.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2017, as of November 2017.
  13. Reichert JM. Antibodies to watch in 2017. MAbs 2017; 9(2):167-181.
    This paper summaries the late-stage clinical pipeline of antibody therapeutics, antibodies in regulatory review and those approved in 2016, as of November 2016.

Select pipeline data derived from this research is available in the Members Only section of the Society’s website.

In addition, the Adaptive Immune Receptor Repertoire Community of The Antibody Society has endorsed and published papers including:

  1. Arnaout RA, Prak ETL, Schwab N, Rubelt F. Adaptive Immune Receptor Repertoire Community. The Future of Blood Testing Is the Immunome. (Frontiers in Immunology, 2021).
  2. Christley et al. The ADC API: a web API for the programmatic query of the AIRR Data Commons (Frontiers in Big Data, 2020).
    This paper outlines the API (Application Programming Interface) for curating and sharing data in the AIRR Data Commons (ADC).
  3. Lees et al. OGRDB: a reference database of inferred immune receptor genes introduces a new database for storing immunoglobulin and T-cell receptor genes inferred from AIRR-seq data (Nucleic Acids Research, 2020).
    This paper describes the Open Germline Receptor Database (https://ogrdb.airr-community.org), a public resource for the submission, review and publication of previously unknown receptor germline sequences together with supporting evidence.
  4. Ohlin et al. Inferred Allelic Variants of Immunoglobulin Receptor Genes: A System for Their Evaluation, Documentation, and Naming (Frontiers in Immunology, 2019)
    This paper summarizes recommendations developed by the IARC—focusing, to begin with, on human IGHV genes—with the goal of facilitating the acceptance of inferred allelic variants of germline IGHV genes.
  5. Vander Heiden et al. AIRR Community Standardized Representations for Annotated Immune Repertoires (Frontiers in Immunology, 2018)
    This paper describes the standardized data representations for storing and sharing annotated antibody and T cell receptor data.
  6. Rubelt et al. Adaptive Immune Receptor Repertoire Community recommendations for sharing immune-repertoire sequencing data (Nature Immunology, 2017, 18(12):1274-1278)
    This paper reports the Community’s recommendations for a minimal set of metadata that should be used to describe an AIRR-seq data set when published or when deposited in a AIRR-compliant repository.
  7. Breden et al. Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data (Frontiers in Immunology, 2017)
    This paper introduced the goals of the AIRR Community and urged researchers to join our efforts.